{
    "nct_id": "NCT05704738",
    "official_title": "A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)",
    "inclusion_criteria": "* Age ≥ 12 to < 18 years at Day 1.\n* Diagnosis of AD (according to American Academy of Dermatology Consensus Criteria [Eichenfield et al, 2014]) that has been present for at least 12 months before signing of informed consent.\n* Body weight ≥ 40 kg at screening.\n* History of inadequate response to TCS of medium to higher potency (with or without TCI).\n* EASI score ≥ 12 at initial screening.\n* EASI score ≥ 16 at Day 1.\n* vIGA-AD score ≥ 3.\n* ≥10% body surface area of AD involvement.\n* Worst pruritus NRS ≥ 4.\nHealthy volunteers allowed\nMust have minimum age of 12 Years\nMust have maximum age of 17 Years",
    "exclusion_criteria": "* Treatment with a biological product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1.\n* Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1:\n\n  1. Systemic corticosteroids\n  2. Non-biologic, non-targeted systemic immunosuppressants\n  3. Phototherapy\n  4. Oral or Topical Janus kinase inhibitors\n* Treatment with any of the following medications or therapies within 1 week, prior to Day 1:\n\n  1. TCS of any potency\n  2. TCI\n  3. Topical phosphodiesterase 4 inhibitors\n  4. Other topical immunosuppressive agents",
    "miscellaneous_criteria": ""
}